NASDAQ$MMSI

Merit Medical Systems Inc · Q3 2020 earnings

Q3 2020 earnings · · Investor relations

Briefing

Merit Medical's financial performance remained stable with a slight revenue increase and improved profitability, driven by expense control and strategic initiatives.

Merit Medical reported a slight increase in worldwide revenue for Q3 2020, alongside significant growth in non-GAAP operating profit and EPS. The company is focused on enhancing efficiency and is on track with its plan to consolidate facilities and move production lines.

  • Worldwide revenue increased by 0.4% to $244.0 million compared to Q3 2019.
  • Non-GAAP EPS increased to $0.42, compared to $0.28 in Q3 2019.
  • GAAP operating margin improved to 0.0% from (1.2)% in Q3 2019.
  • The company is on track to complete the movement of more than 14 production lines and consolidate several facilities before year end.

Headline financials

Total Revenue

$244M

Previous: $243M+0.4%
EPS (adj)

$0.42

Previous: $0.28+50.0%
GAAP Operating Margin

0.0%

Previous: -1.2%+100.0%
Non-GAAP Operating Margin

15.0%

Previous: 9.2%+63.0%
Capital Expenditures

-$35.6M

Previous: -$58.1M+38.7%
Free Cash Flow

-$38.6M

Previous: -$61.5M+37.2%
Net Income

-$3.01M

Previous: -$3.4M+11.4%
Operating Income

$64K

Previous: -$2.88M+102.2%
Gross Profit

$102M

Previous: $104M-2.0%
Cash & Equivalents

$44.6M

Previous: $37.3M+19.4%
Total Assets

$1.67B

Previous: $1.76B-5.2%
Stock-Based Comp

$4.06M

Previous: $2.63M+54.7%

Revenue & EPS history

Merit Medical · Revenue · Quarterly

$244M

Q3 2020+0.4%vs Q3 2019
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Revenue by segment

Merit Medical · $7.56M total across 1 segment · Q3 2020

  • Endoscopy
    $7.56M-12.3%

Forward guidance

Merit Medical updated its fiscal year 2020 revenue guidance. They estimate net revenue to be in the range of $950.0 million to $959.0 million and non-GAAP net income to be in the range of $85.5 million to $88.5 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2020

Historical avgQ3 2020

-0.1%

Avg return

Earnings day

-0.3%

Avg return

5 days after

+1.8%

Avg return

30 days after

52%

34 / 65 earnings

Positive

+16.5%

Q3 2014

Best reaction

-31.4%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+5.2%-6.8%-2.8%
Q4 2025-3.8%-7.2%-16.6%
Q3 2025+5.1%+4.9%+4.3%
Q1 2025-0.1%-0.2%+0.7%
Q4 2024-1.5%+1.0%+1.9%
Q3 2024+2.9%+3.3%+8.3%
Q2 2024+4.0%+5.0%+13.4%
Q1 2024+2.1%+5.2%+7.8%
Q4 2023-5.3%-4.9%-5.9%
Q3 2023+7.7%+7.3%+12.9%
Q2 2023-9.6%-8.3%-16.4%
Q1 2023+4.7%+5.1%+4.3%
Q4 2022+2.8%+1.3%+3.7%
Q3 2022+7.0%+14.6%+19.6%
Q2 2022+6.0%+10.6%+10.0%
Q1 2022-3.7%-4.7%-5.2%
Q4 2021+8.4%+9.3%+5.0%
Q3 2021-1.8%-5.1%-3.5%
Q2 2021+7.6%+3.9%+10.1%
Q1 2021-0.2%+1.4%-5.3%
Q4 2020-1.8%-0.4%+1.9%
Q3 2020+5.2%+1.3%+11.7%
Q2 2020+4.3%-1.9%+11.6%
Q1 2020+9.0%+6.5%+21.4%
Q4 2019+0.4%-9.5%-17.0%
Q3 2019-31.4%-15.5%-7.0%
Q2 2019-24.7%-26.2%-37.2%
Q1 2019-1.9%-4.7%-9.4%
Q4 2018-4.3%-2.1%+1.6%
Q3 2018-4.1%-5.3%-3.5%
Q2 2018+2.8%-3.1%+3.3%
Q1 2018+2.8%+7.5%+18.7%
Q4 2017-2.1%-5.1%-3.3%
Q3 2017-9.7%-11.0%+4.6%
Q2 2017+4.8%+5.5%+4.6%
Q1 2017+8.2%+8.2%+11.6%
Q4 2016+5.9%+4.8%+0.0%
Q3 2016-5.0%-5.0%+5.2%
Q2 2016+6.1%+6.7%+6.5%
Q1 2016+2.5%
Q4 2015-2.8%
Q3 2015-27.3%
Q2 2015+10.7%
Q1 2015+9.5%
Q4 2014+7.7%
Q3 2014+16.5%
Q2 2014-14.4%
Q1 2014-5.4%
Q4 2013+1.2%
Q3 2013+15.4%
Q2 2013+7.6%
Q1 2013-13.9%
Q4 2012-14.7%
Q3 2012-2.8%
Q2 2012-0.5%
Q1 2011-0.7%
Q4 2011-0.7%
Q1 2012+1.1%
Q1 2010-1.6%
Q4 2009-1.6%
Q3 2010-1.1%
Q3 2011-1.1%
Q2 2011+1.6%
Q2 2010+1.6%
Q4 2010+1.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro